News and Announcements
YPB Completes Oversubscribed A$4.5 million Institutional Placement
- Published May 24, 2016 5:29PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
24th May 2016, ASX Announcement
Highlights:
- Placement of 18.75 million new ordinary shares at $0.24 per share
- Excellent demand for from new and existing shareholders
- Six new institutions join the register
- Capital raised to fund acceleration of business development and product R&D
Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX code: YPB) has successfully undertaken an institutional placement of new fully paid ordinary shares to raise A$4.5 million.
The placement was strongly supported by new and existing investors, with the addition of six new institutions to the register.
Under the placement, YPB will issue 18.75 million new ordinary shares at a price of 0.24 per share.
To view the full announcement, please click on the button below.
To view the Institutional Placement Presentation, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
